Rice Biotech Launch Pad welcomes Carolyn Ng to external advisory board
Rice Biotech Launch Pad has appointed Carolyn Ng, a business unit partner at TPG Life Sciences Innovations, to its external advisory board. Ng brings significant expertise in biotech and company building, with extensive experience guiding early to midstage companies across various therapeutic areas.
Currently leading investments at TPG Life Sciences Innovations in San Francisco, Ng serves on multiple boards including Mbrace Therapeutics, Adcendo Aps, and Bicara Therapeutics (NASDAQ: BCAX). Her appointment marks her as the 16th member of the Launch Pad's external advisory board, joining leaders from various prestigious institutions and companies.
The Rice Biotech Launch Pad, based in Houston, focuses on accelerating the translation of Rice University's health and medical technology discoveries into practical medical solutions.
Rice Biotech Launch Pad ha nominato Carolyn Ng, partner di unità aziendale presso TPG Life Sciences Innovations, nel suo consiglio consultivo esterno. Ng apporta una significativa esperienza nel settore biotecnologico e nella creazione di aziende, con un ampio background nella guida di società in fase iniziale e intermedia in diversi ambiti terapeutici.
Attualmente responsabile degli investimenti presso TPG Life Sciences Innovations a San Francisco, Ng siede in diversi consigli di amministrazione, tra cui Mbrace Therapeutics, Adcendo Aps e Bicara Therapeutics (NASDAQ: BCAX). La sua nomina la rende il sedicesimo membro del consiglio consultivo esterno del Launch Pad, affiancando leader provenienti da varie istituzioni e aziende di prestigio.
Il Rice Biotech Launch Pad, con sede a Houston, si concentra sull'accelerazione della trasformazione delle scoperte in ambito sanitario e tecnologico dell'Università Rice in soluzioni mediche concrete.
Rice Biotech Launch Pad ha designado a Carolyn Ng, socia de unidad de negocios en TPG Life Sciences Innovations, para su consejo asesor externo. Ng aporta una amplia experiencia en biotecnología y creación de empresas, con un extenso recorrido guiando compañías en etapas tempranas y medias en diversas áreas terapéuticas.
Actualmente liderando inversiones en TPG Life Sciences Innovations en San Francisco, Ng forma parte de varios consejos, incluyendo Mbrace Therapeutics, Adcendo Aps y Bicara Therapeutics (NASDAQ: BCAX). Su nombramiento la convierte en la decimosexta miembro del consejo asesor externo del Launch Pad, uniéndose a líderes de prestigiosas instituciones y compañías.
El Rice Biotech Launch Pad, con sede en Houston, se dedica a acelerar la transformación de los descubrimientos en tecnología médica y de salud de la Universidad Rice en soluciones médicas prácticas.
Rice Biotech Launch Pad는 TPG Life Sciences Innovations의 사업부 파트너인 Carolyn Ng를 외부 자문위원회에 임명했습니다. Ng는 바이오테크 및 기업 구축에 대한 풍부한 전문지식을 보유하고 있으며, 다양한 치료 분야에서 초기 및 중기 단계 기업을 이끄는 경험이 많습니다.
현재 샌프란시스코에 위치한 TPG Life Sciences Innovations에서 투자를 총괄하고 있는 Ng는 Mbrace Therapeutics, Adcendo Aps, Bicara Therapeutics (NASDAQ: BCAX) 등 여러 이사회에서 활동하고 있습니다. 그녀의 임명으로 Launch Pad 외부 자문위원회는 16번째 멤버를 맞이하게 되었으며, 다양한 명망 있는 기관과 기업의 리더들과 함께 하게 되었습니다.
휴스턴에 기반을 둔 Rice Biotech Launch Pad는 Rice 대학교의 보건 및 의료 기술 발견을 실질적인 의료 솔루션으로 신속히 전환하는 데 주력하고 있습니다.
Rice Biotech Launch Pad a nommé Carolyn Ng, partenaire d’unité commerciale chez TPG Life Sciences Innovations, à son conseil consultatif externe. Ng apporte une expertise significative en biotechnologie et en création d’entreprises, avec une vaste expérience dans l’accompagnement d’entreprises en phase précoce à intermédiaire dans divers domaines thérapeutiques.
Actuellement responsable des investissements chez TPG Life Sciences Innovations à San Francisco, Ng siège à plusieurs conseils d’administration, notamment ceux de Mbrace Therapeutics, Adcendo Aps et Bicara Therapeutics (NASDAQ : BCAX). Sa nomination fait d’elle la 16e membre du conseil consultatif externe du Launch Pad, rejoignant ainsi des leaders issus de diverses institutions et entreprises prestigieuses.
Basé à Houston, le Rice Biotech Launch Pad se concentre sur l’accélération de la transformation des découvertes en technologies de santé et médicales de l’Université Rice en solutions médicales concrètes.
Rice Biotech Launch Pad hat Carolyn Ng, Geschäftseinheitenpartnerin bei TPG Life Sciences Innovations, in seinen externen Beirat berufen. Ng bringt umfangreiche Expertise in Biotechnologie und Unternehmensaufbau mit und verfügt über umfassende Erfahrung in der Begleitung von Unternehmen in frühen bis mittleren Entwicklungsphasen in verschiedenen therapeutischen Bereichen.
Derzeit leitet Ng die Investitionen bei TPG Life Sciences Innovations in San Francisco und ist Mitglied mehrerer Aufsichtsräte, darunter Mbrace Therapeutics, Adcendo Aps und Bicara Therapeutics (NASDAQ: BCAX). Mit ihrer Ernennung wird sie das 16. Mitglied des externen Beirats des Launch Pad und tritt damit einer Gruppe von Führungskräften aus renommierten Institutionen und Unternehmen bei.
Der in Houston ansässige Rice Biotech Launch Pad konzentriert sich darauf, Entdeckungen im Bereich Gesundheits- und Medizintechnologie der Rice University schnell in praktische medizinische Lösungen umzusetzen.
- Strategic addition of experienced biotech investor with proven track record in early-stage companies
- Strengthens Launch Pad's ability to transform research into commercial therapies
- Enhances connection to major biotech investment networks through TPG Life Sciences
- None.
"Carolyn's deep understanding of translational science, combined with her passion for fostering high-impact ventures, makes her an ideal addition to the board," said Omid Veiseh, professor of bioengineering at Rice and faculty director of the Launch Pad. "She shares our commitment to transforming early cutting-edge research into breakthrough therapies that address real-world medical challenges."
"Carolyn brings exceptional insight into the strategic and operational needs of growing biotech companies such as the ones we are aiming to form at the Launch Pad," said Paul Wotton, executive director of the Launch Pad. "Her global perspective on life sciences innovation will be invaluable as we continue to grow."
"As Houston rapidly emerges as a leading biotech hub, the groundbreaking research conducted at Rice University will be a key driver of its long-term success," Ng said. "The Launch Pad's unique approach, rooted in academic excellence and entrepreneurial focus, will be fundamental in transforming that research into successful therapies. I look forward to contributing my knowledge and experience to support the Launch Pad's continued growth and its mission to advance innovative therapies from lab to market."
In her current position at TPG Life Sciences Innovations in
Ng is the 16th member of the Launch Pad's external advisory board. The other members are David Allison, managing director at Westlake BioPartners; Jason Bock, founder and CEO of CTMC; Albert Cha, managing partner of Frazier Life Sciences; Rima Chakrabarti, partner at KdT Ventures and CEO of Sentinel BioTherapeutics; John Flavin, founder and CEO of Portal Innovations, co-founder and chairman of Pyxis Oncology and entrepreneurial adviser of Argonne National Laboratory; Pierre Jacquet, managing director and vice chairman of L.E.K.'s health care consulting practice; Robert Langer, professor at the David H. Koch Institute for Integrated Research at the Massachusetts Institute of Technology; Dennis Lee, senior program officer, accelerator at the Bill and Melinda Gates Foundation; William McKeon, president and CEO of the Texas Medical Center; Ferran Prat, chief commercial officer at BostonGene; Josh Richardson, managing director and senior investor on the life sciences investigating team at Goldman Sachs; Robert Ruffolo, chairman of Aragen Biosciences; David Schull, president of Russo Partners; Kevin Sheridan, managing director and joint global head of health care investment banking at Jefferies; and Lisa Wright, president and CEO of Community Health Choice.
About the Rice Biotech Launch Pad:
The Rice Biotech Launch Pad is a Houston-based accelerator focused on expediting the translation of Rice University's health and medical technology discoveries into cures. This initiative is designed to help advance internally discovered platform technologies from concept to clinical studies and commercialization. The Rice Biotech Launch Pad will identify and support highly differentiated projects while driving the expansion of Houston as a world-class medical innovation ecosystem. The accelerator will bring together local researchers with a network of industry executives. For more information, please visit https://biotechlaunchpad.rice.edu/.
Media Contacts:
Russo Partners
David Schull or Liz Phillips
(347) 956-7697
david.schull@russopartnersllc.com
elizabeth.phillips@russopartnersllc.com
View original content:https://www.prnewswire.com/news-releases/rice-biotech-launch-pad-welcomes-carolyn-ng-to-external-advisory-board-302518437.html
SOURCE Rice University
FAQ
Who is Carolyn Ng and what is her role at Rice Biotech Launch Pad?
What companies is Carolyn Ng currently involved with as a board member?
How many members are on the Rice Biotech Launch Pad's external advisory board?
What is the main purpose of the Rice Biotech Launch Pad?
What is Carolyn Ng's background and experience in the biotech industry?
